Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?

被引：10
|
作者：
Furness, Andrew Js [1 ,2 ]
Quezada, Sergio A. [1 ]
Peggs, Karl S. [1 ]
机构：
[1] UCL, Canc Immunol Unit, Inst Canc, London, England
[2] Royal Marsden NHS Fdn Trust, London, England
来源：
IMMUNOTHERAPY | 2016年 / 8卷 / 07期
关键词：
CTLA-4; heterogeneity; neoantigens; PD-1; TUMOR-INFILTRATING LYMPHOCYTES; CYTOLYTIC T-LYMPHOCYTES; METASTATIC MELANOMA; CTLA-4; BLOCKADE; UNTREATED MELANOMA; HLA-A2; MELANOMAS; LUNG-CANCER; IPILIMUMAB; ANTIGEN; NIVOLUMAB;
D O I：
10.2217/imt-2016-0064
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：763 / 766
页数：4
相关论文
共 50 条
  • [1] The role of neoantigen in immune checkpoint blockade therapy
    Yi, Ming
    Qin, Shuang
    Zhao, Weiheng
    Yu, Shengnan
    Chu, Qian
    Wu, Kongming
    [J]. EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2018, 7
  • [2] The role of neoantigen in immune checkpoint blockade therapy
    Ming Yi
    Shuang Qin
    Weiheng Zhao
    Shengnan Yu
    Qian Chu
    Kongming Wu
    [J]. Experimental Hematology & Oncology, 7
  • [3] IMMUNE CHECKPOINT BLOCKADE ENHANCES EFFICACY OF NEOANTIGEN VACCINE
    不详
    [J]. CANCER DISCOVERY, 2022, 12 (06) : 1408 - 1408
  • [4] Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
    Katrin Aslan
    Verena Turco
    Jens Blobner
    Jana K. Sonner
    Anna Rita Liuzzi
    Nicolás Gonzalo Núñez
    Donatella De Feo
    Philipp Kickingereder
    Manuel Fischer
    Ed Green
    Ahmed Sadik
    Mirco Friedrich
    Khwab Sanghvi
    Michael Kilian
    Frederik Cichon
    Lara Wolf
    Kristine Jähne
    Anna von Landenberg
    Lukas Bunse
    Felix Sahm
    Daniel Schrimpf
    Jochen Meyer
    Allen Alexander
    Gianluca Brugnara
    Ralph Röth
    Kira Pfleiderer
    Beate Niesler
    Andreas von Deimling
    Christiane Opitz
    Michael O. Breckwoldt
    Sabine Heiland
    Martin Bendszus
    Wolfgang Wick
    Burkhard Becher
    Michael Platten
    [J]. Nature Communications, 11
  • [5] Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
    Aslan, Katrin
    Turco, Verena
    Blobner, Jens
    Sonner, Jana K.
    Liuzzi, Anna Rita
    Nunez, Nicolas Gonzalo
    De Feo, Donatella
    Kickingereder, Philipp
    Fischer, Manuel
    Green, Ed
    Sadik, Ahmed
    Friedrich, Mirco
    Sanghvi, Khwab
    Kilian, Michael
    Cichon, Frederik
    Wolf, Lara
    Jaehne, Kristine
    von Landenberg, Anna
    Bunse, Lukas
    Sahm, Felix
    Schrimpf, Daniel
    Meyer, Jochen
    Alexander, Allen
    Brugnara, Gianluca
    Roeth, Ralph
    Pfleiderer, Kira
    Niesler, Beate
    von Deimling, Andreas
    Opitz, Christiane
    Breckwoldt, Michael O.
    Heiland, Sabine
    Bendszus, Martin
    Wick, Wolfgang
    Becher, Burkhard
    Platten, Michael
    [J]. NATURE COMMUNICATIONS, 2020, 11 (01)
  • [6] Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade
    Richman, Lee P.
    Vonderheide, Robert H.
    Rech, Andrew J.
    [J]. CELL SYSTEMS, 2019, 9 (04) : 375 - +
  • [7] Cancer driver screens identifyregulators of immune checkpoint blockade therapy response.
    Zhou, Wenrong
    Peng, Zhengang
    Huang, Dawei
    Long, Min
    Song, Tianyu
    Ni, Siyuan
    Cang, Yong
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [8] Biomarkers for Response to Immune Checkpoint Blockade
    Ganesan, Shridar
    Mehnert, Janice
    [J]. ANNUAL REVIEW OF CANCER BIOLOGY, VOL 4, 2020, 4 : 331 - 351
  • [9] Hallmarks of response to immune checkpoint blockade
    Alexandria P Cogdill
    Miles C Andrews
    Jennifer A Wargo
    [J]. British Journal of Cancer, 2017, 117 : 1 - 7
  • [10] Hallmarks of response to immune checkpoint blockade
    Cogdill, Alexandria P.
    Andrews, Miles C.
    Wargo, Jennifer A.
    [J]. BRITISH JOURNAL OF CANCER, 2017, 117 (01) : 1 - 7
12345